RNS Number : 3593X

GlaxoSmithKline PLC

20 February 2017

GlaxoSmithKline plc (the 'Company')

Shares withheld or sold to meet tax liabilities

Following the vesting of awards granted in 2014 under the GlaxoSmithKline 2009 Performance Share Plan on 16 February 2017 and as notified on 17 February 2017, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them ('PCA") in Ordinary Shares and in American Depositary Shares (ADSs) of the Company arising from the sale or withholding of Ordinary Shares or ADSs to meet tax liabilities. This notification also includes the sale further to the vesting of awards granted in 2012 to Sir Andrew Witty which were subject to an additional holding period.   

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Andrew Witty

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2012 and 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	9,057
£16.2437	166
£16.2437	55,441

d)

Aggregated information

Aggregated volume Price

                                                                                               64,664                                                                                 £16.2437

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

CEO Designate

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	19,218

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing and Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	14,957

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	32,529

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$40.57	1,255

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	27,371

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$40.57	10,082

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	10,738

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	15,320

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

SVP, Communications & Government Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	7,307

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053 

b)

Nature of the transaction

The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$40.57	13,035

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	32,996

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£16.2437	2,197

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr K Slaoui

b)

Position/status

PCA of Dr M M Slaoui (Chairman, Global Vaccines)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$40.57	249

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

n/a

This information is provided by RNS

The company news service from the London Stock Exchange

END DSHEBLFLDLFEBBE